2012-10-05 16:30:53 - Recently published research from Global Markets Direct, "Neutropenia - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neutropenia. Neutropenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468363_neutropenia_pipeline_review_h2_2012.a ..


Scope

* A snapshot of the global therapeutic scenario for Neutropenia.
* A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Neutropenia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Neutropenia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neutropenia Overview
Therapeutics Development
An Overview of Pipeline Products for Neutropenia
Neutropenia Therapeutics under Development by Companies
Neutropenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Neutropenia Therapeutics - Products under Development by Companies
Neutropenia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Neutropenia Therapeutics Development
GlaxoSmithKline plc
Gamida Cell Ltd.
Mochida Pharmaceutical Co., Ltd.
STADA Arzneimittel AG
Ligand Pharmaceuticals Incorporated
Lupin Limited
NexMed, Inc.
Telik, Inc.
Zenotech Laboratories Limited
ProMetic Life Sciences Inc.
Lipoxen PLC
Green Cross Corporation
Genexine Co., Ltd.
Bolder Biotechnology, Inc.
Welichem Biotech Inc.
PharmaEssentia Corporation
ImmuneRegen BioSciences, Inc.
Pfenex Inc.
Mycenax Biotech Inc.
Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Homspera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ezatiostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
peginterferon alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GX-G3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WBI-2100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polysialic-granulocyte colony stimulating factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegylated recombinant human granulocyte colony-stimulating factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GranNEX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caspofungin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
daptomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Busulfan + Cyclosporine + Fludarabine + Methotrexate + Methylprednisolone + Filgrastim + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Thymocyte Globulin + Fludarabine + Thiotepa + T Cell Depleted Haplocompatible Peripheral Blood Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
liposomal amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nevirapine - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468363&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.